VEGFA and pulmonary arterial hypertension: Yet, anti-VEGF agents are not entirely protective in all patients with diabetic retinopathy [5] and there are safety concerns for retinopathy of prematurity including reduced circulating VEGFA levels leading to neurocognitive decline and pulmonary hypertension [8, 9].